Analyst Price Targets — GLP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 2, 2026 1:18 pm | Selman Akyol | Stifel Nicolaus | $46.00 | $47.49 | StreetInsider | Global Partners, L.P. (GLP) PT Raised to $46 at Stifel, Hold Rating Maintained |
| November 7, 2022 7:04 pm | Selman Akyol | Stifel Nicolaus | $35.00 | $29.96 | TheFly | Global Partners upgraded to Buy from Hold at Stifel |
Latest News for GLP
MichaelAaron Flicker examines the growing impact of GLP-1 medications on consumer behavior, noting that roughly one in five American households has someone using a GLP-1 drug. He explains how that trend is reshaping spending habits and discusses the implications for restaurants as well as food and beverage stocks.
Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are already deep into the development process with comparable programs.
Novo Nordisk is pulling ahead of Eli Lilly in the market for oral weight loss medicines. Eli Lilly has several tricks up its sleeve that could help it make some progress in this niche.
Following a careful analysis of the Zacks Oil and Gas - Refining & Marketing MLP industry, we advise keeping an eye on three stocks: SPH, NGL and GLP.
Fractyl Health NASDAQ: GUTS reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its Revita procedure helped patients maintain a larger share of GLP-1-induced weight loss after discontinuing GLP-1 therapy compared with a sham procedure.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GLP.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.